Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers
出版年份 2022 全文链接
标题
Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-17
DOI
10.1007/s00259-021-05672-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PET imaging of TIGIT expression on tumor-infiltrating lymphocytes
- (2021) Travis Shaffer et al. CLINICAL CANCER RESEARCH
- TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
- (2021) Jinah Yeo et al. Pharmaceuticals
- First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET
- (2021) Xin Zhou et al. JOURNAL OF NUCLEAR MEDICINE
- A Novel D Peptide Identified by Mirror‐image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy
- (2020) Xiuman Zhou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
- (2020) David Kung-Chun Chiu et al. GASTROENTEROLOGY
- TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma
- (2020) Zhi-Zhang Yang et al. CLINICAL CANCER RESEARCH
- Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
- (2020) Zhaopei Liu et al. Journal for ImmunoTherapy of Cancer
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer
- (2019) Yan Xing et al. JOURNAL OF NUCLEAR MEDICINE
- Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
- (2019) Lawrence P. Andrews et al. NATURE IMMUNOLOGY
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Peptide-based PET quantifies target engagement of PD-L1 therapeutics
- (2018) Dhiraj Kumar et al. JOURNAL OF CLINICAL INVESTIGATION
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
- (2018) A. N. Niemeijer et al. Nature Communications
- TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- (2017) Nicholas A. Manieri et al. TRENDS IN IMMUNOLOGY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering
- (2012) K. F. Stengel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
- (2009) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started